MIRM - NASDAQ
Mirum Pharmaceuticals, Inc.
$91.83
-0.016%Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
At a Glance
Live SnapshotMirum Pharmaceuticals, Inc. Management Team
Mr. Paul K. Ross
Chief Compliance Officer
Ms. Lara Longpre MBA, MSC
Chief Development Officer
Compensation
$678,200
Mr. Christopher Peetz
Chief Executive Officer & Director
Compensation
$1,535,850
Mr. Eric H. Bjerkholt M.B.A.
Chief Financial Officer
Compensation
$860,887
Mr. Eric H. Bjerkholt M.B.A., M.S.
Chief Financial Officer
Compensation
$860,887
Mr. Douglas T. Sheehy J.D.
Chief Legal Officer
Dr. Joanne M. J. Quan M.D.
Chief Medical Officer
Compensation
$827,424
Mr. Peter Radovich M.B.A., Ph.D.
Chief Operating Officer & President
Compensation
$990,050
Ms. Erin Campany
Chief People Officer
Dr. Pamela Vig Ph.D.
Chief Scientific Officer
Compensation
$678,200
Dr. Jean-Luc Girardet Ph.D.
Chief Technical Officer
Mr. Andrew McKibben
Senior Vice President, Strategic Finance & Investor Relations
Mirum Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have purchased $9.00M and sold $30.53M worth of MIRM shares, resulting in $21.53M of net selling activity.
3 Months
0
0.00
85.4K
7.90M
-7.9M
-$7.90M
3-6 Months
131.4K
9.00M
105.1K
9.11M
-108K
-$108K
6-9 Months
0
0.00
111.1K
8.04M
-8.0M
-$8.04M
9-12 Months
0
0.00
94.2K
5.48M
-5.5M
-$5.48M
Top Buyers
Heron Patrick J
Director
$9.00M
Top Sellers
Grey Michael G
Director
$11.10M
Peetz Christopher
Director, Officer: Chief Executive Officer
$10.97M
Radovich Peter
Officer: President And Coo
$2.32M
Bjerkholt Eric
Officer: Chief Financial Officer
$1.63M
Quan Joanne
Officer: Chief Medical Officer
$1.46M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $21.53M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
MIRM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 23, 2026 | December 31, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | April 14, 2025 | April 14, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 23, 2024 | April 23, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | May 01, 2023 | June 12, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 22, 2022 | June 02, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 14, 2021 | June 04, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 29, 2020 | June 11, 2020 | 2020 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.